MedTrace Logo

Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)

NCT06250790 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-02-16

No results posted yet for this study

Summary

The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.

Conditions

Interventions

DIAGNOSTIC_TEST

Coronary CT angiography and FFRct analysis

A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.

Sponsors & Collaborators

  • Pauls Stradins Clinical University Hospital

    lead OTHER

Principal Investigators

  • Dainis Krievins, MD, PhD · Institute of Science, Pauls Stradins Clinical University Hospital

  • Andrejs Erglis, MD, PhD · Pauls Stradins Clinical University Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2026-02-15
Completion
2029-02-15

Countries

  • Latvia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250790 on ClinicalTrials.gov